Allogene Therapeutics Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, Allogene Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $9.00. The average 1-year stock price forecast is 631.71% higher than the current stock price, while the lowest is $4.00 (+225.20%) and the highest is $14 (+1,038.21%).

Price Target: $9.00 (+631.71%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$4.00	$9.00	$9.00	$14
Change	+225.20%	+631.71%	+631.71%	+1038.2%

Analyst Ratings

The average analyst rating for Allogene Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Apr '26	May '26	Jun '26	Jul '26	Aug '26	Sep '26
Strong Buy	10	9	8	8	8	8
Buy	3	3	3	3	3	3
Hold	2	2	2	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	15	14	13	12	12	12

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
John Newman Canaccord Genuity	Canaccord Genuity	Buy Maintains $14	Buy	Maintains	$14	+1,038.21%	Sep 30, 2026
Brian Cheng J.P. Morgan	J.P. Morgan	Hold Maintains n/a	Hold	Maintains	n/a	n/a	Aug 17, 2026
Tyler Van Buren TD Cowen	TD Cowen	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Aug 13, 2026
Unknown Analyst UBS No rating	UBS	Buy Reiterates $8	Buy	Reiterates	$8	+550.41%	Aug 13, 2026
Luca Issi RBC Capital	RBC Capital	Buy Reiterates $9	Buy	Reiterates	$9	+631.71%	Aug 13, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

3.74M

Revenue Next Year

12.09M

from 3.74M

223.15%

from 3.74M

EPS This Year

-0.58

from -0.85

EPS Next Year

-0.62

from -0.58

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	114.09M	156.00K	95.00K	22.00K	-	3.74M
Operating Income	-180.19M	-335.54M	-314.49M	-257.48M	-206.93M	-199.08M
Net Income	-182.05M	-340.41M	-327.27M	-257.59M	-190.89M	-185.34M
EPS	-	-	-	-	-0.85	-0.58
Free Cash Flow	-	-	-	-	-149.63M	-126.33M
No. Analysts	-	-	-	-	-	10

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	5.0M
Avg	3.7M
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	1,584.5%
Avg	223.1%
Low	-100.0%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.38
Avg	-0.58
Low	-0.68

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-